Proxelan

Phase 3Small molecule

UUniversity of Pisa

Proxelan is one of 17 small molecule programs targeting Chronic Prostatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic ProstatitisActive, not recruiting

Chronic ProstatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Chronic Prostatitis

#DrugCompanyPhaseTrials

Uroxatral

AAdvanz Pharma

Phase 3

1 2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Avodart

Akero Therapeutics

Phase 3

1 4

Actimmune

HHorizon Therapeutics Ireland DAC

Rapaflo

1 6

Cipro

Bayer

Phase 2

1 7

Thalomid

Bristol-Myers Squibb

Phase 2

1 8

OM-89

AAJU Pharm Co., Ltd.

Approved

1 9

Tamsulosin OCAS

Astellas

Phase 2

2 10

CC-10004

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Prostatitis1 trial

Effects of Proxelan Somministration in Patients With Chronic Prostatitis

Unknown status·UUniversity of Pisa·Phase 3·NCT03629769·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Proxelan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proxelan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proxelan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pisa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Pisa

Proxelan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Prostatitis1 trial

References

Drug Info

Quick Facts

Related News